<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00391755</url>
  </required_header>
  <id_info>
    <org_study_id>06-013R</org_study_id>
    <nct_id>NCT00391755</nct_id>
  </id_info>
  <brief_title>A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches</brief_title>
  <official_title>A Double-Blind Placebo-Controlled Trial of Rozerem in Migraine Headaches</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Charlottesville Neuroscience</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda Pharmaceuticals North America, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Charlottesville Neuroscience</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the effect of Rozerem, a high affinity MT1 and MT2, low affinity 5-HT2B receptor
      agonist used for insomnia, as a migraine prophylactic agent.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In a recent, large study of migraineurs, over half reported difficulties with sleep
      initiation or maintenance. Those who had shorter average sleep times reported more severe
      headaches. Poor sleep has been associated with increased frequency and severity of migraines.
      The improvement of migraine frequency with improved sleep hygiene has been documented.

      PET imaging has shown increased regional cerebral blood flow to neural structures involved in
      the sleep wake cycle during migraine headaches. Polysomnography has shown specific headache
      types to occur in specific sleep stages.

      Melatonin has been effective primarily in headache due to delayed sleep phase syndrome.
      Recent studies support the efficacy of melatonin in treating migraine. The purpose of this
      study is to examine the efficacy of Rozerem as a prophylactic migraine medication. If
      effective, the benefits of the drug as a prophylactic agent for migraine include the
      tolerability of the drug and the possible secondary benefit of improvement in sleep.

      Hypothesis: Rozerem will decrease migraine frequency due to the improvement in sleep and
      possibly due to the shared neurophysiology of sleep and migraine affected by melatonin.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Failure to recruit necessary number of patients.
  </why_stopped>
  <start_date>October 2006</start_date>
  <completion_date type="Actual">October 2009</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Statistically significant reduction in migraine headaches in the Rozerem treated group.</measure>
    <time_frame>4 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Improvement in sleep satisfaction in the Rozerem treated group.</measure>
    <time_frame>4 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Migraine Headache</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ramelteon 8 mg po qhs with sleep and migraine journal</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo po qhs with sleep and migraine journal</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ramelteon</intervention_name>
    <description>ramelteon 8mg po qhs with sleep and headache diary
placebo 1 po qhs with sleep and headache diary</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <other_name>Rozerem</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-65

          -  3-8 Migraine headaches/month

          -  Able to understand and comply with the study

        Exclusion Criteria:

          -  Currently on migraine prophylaxis

          -  Currently on sleep medication &gt; 4days/month

          -  Currently on Fluvoxamine

          -  Untreated psychiatric or sleep disorders

          -  MRI abnormalities other than those attributable to migraine headaches

          -  Abnormalities on neurological exam other than known neurological disorders
             unassociated with migraine or sleep

          -  Known disorders of prolactin

          -  Bipolar disorder

          -  Hepatic disease

          -  Pregnancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Patricia J Shipley, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Charlottesville Neuroscience</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Patricia Shipley, MD</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Sahota PK, Dexter JD. Sleep and headache syndromes: a clinical review. Headache. 1990 Jan;30(2):80-4. Review.</citation>
    <PMID>2406223</PMID>
  </reference>
  <reference>
    <citation>Kelman L, Rains JC. Headache and sleep: examination of sleep patterns and complaints in a large clinical sample of migraineurs. Headache. 2005 Jul-Aug;45(7):904-10.</citation>
    <PMID>15985108</PMID>
  </reference>
  <reference>
    <citation>Boardman HF, Thomas E, Millson DS, Croft PR. Psychological, sleep, lifestyle, and comorbid associations with headache. Headache. 2005 Jun;45(6):657-69.</citation>
    <PMID>15953298</PMID>
  </reference>
  <reference>
    <citation>Bruni O, Galli F, Guidetti V. Sleep hygiene and migraine in children and adolescents. Cephalalgia. 1999 Dec;19 Suppl 25:57-9.</citation>
    <PMID>10668125</PMID>
  </reference>
  <reference>
    <citation>Bahra A, Matharu MS, Buchel C, Frackowiak RS, Goadsby PJ. Brainstem activation specific to migraine headache. Lancet. 2001 Mar 31;357(9261):1016-7.</citation>
    <PMID>11293599</PMID>
  </reference>
  <reference>
    <citation>Peres MF. Melatonin, the pineal gland and their implications for headache disorders. Cephalalgia. 2005 Jun;25(6):403-11. Review.</citation>
    <PMID>15910564</PMID>
  </reference>
  <reference>
    <citation>Peres MF, Zukerman E, da Cunha Tanuri F, Moreira FR, Cipolla-Neto J. Melatonin, 3 mg, is effective for migraine prevention. Neurology. 2004 Aug 24;63(4):757.</citation>
    <PMID>15326268</PMID>
  </reference>
  <verification_date>February 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 22, 2006</study_first_submitted>
  <study_first_submitted_qc>October 23, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 24, 2006</study_first_posted>
  <last_update_submitted>February 8, 2012</last_update_submitted>
  <last_update_submitted_qc>February 8, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 10, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Charlottesville Neuroscience</investigator_affiliation>
    <investigator_full_name>Patricia Shipley, MD</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Migraine Headache</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Migraine Disorders</mesh_term>
    <mesh_term>Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

